Evidence map›Paper›PMID 30622946›Full record

ArticleFrontiers in bioengineering and biotechnology2018

Characterization of a Putrescine Transaminase From

James L Galman, Deepankar Gahloth, Fabio Parmeggiani, Iustina Slabu, David Leys, Nicholas J Turner

Open access · goldAbstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

James L GalmanSchool of Chemistry, Manchester Institute of Biotechnology, The University of Manchester, Manchester, United Kingdom.
Deepankar GahlothSchool of Chemistry, Manchester Institute of Biotechnology, The University of Manchester, Manchester, United Kingdom.
Fabio ParmeggianiSchool of Chemistry, Manchester Institute of Biotechnology, The University of Manchester, Manchester, United Kingdom.
Iustina SlabuSchool of Chemistry, Manchester Institute of Biotechnology, The University of Manchester, Manchester, United Kingdom.
David LeysSchool of Chemistry, Manchester Institute of Biotechnology, The University of Manchester, Manchester, United Kingdom.
Nicholas J TurnerSchool of Chemistry, Manchester Institute of Biotechnology, The University of Manchester, Manchester, United Kingdom.
University of Manchester · GB

Funding

Biotechnology and Biological Sciences Research Council BB/M017702/1
6 · The paper itself

Abstract

The reductive amination of prochiral ketones using biocatalysts has been of great interest to the pharmaceutical industry in the last decade for integrating novel strategies in the production of chiral building blocks with the intent of minimizing impact on the environment. Amongst the enzymes able to catalyze the direct amination of prochiral ketones, pyridoxal 5'-phosphate (PLP) dependent ω-transaminases have shown great promise as versatile industrial biocatalysts with high selectivity, regioselectivity, and broad substrate scope. Herein the biochemical characterization of a putrescine transaminase from

Indexed as

benzylaminesbiocatalysisgreen chemistryprotein structuretransaminase

Identifiers

PMID30622946
PMCPMC6308316
OpenAlexW2905622252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.